

Effects of Restrictive-prescribing Stewardship on Antibiotic Consumption in Primary Care in China: An Interrupted Time Series Analysis, 2012-2017

Xuemei Wang

Huazhong University of Science and Technology Tongji Medical College

Yuqing Tang

Huazhong University of Science and Technology Tongji Medical College

Chenxi Liu

Huazhong University of Science and Technology Tongji Medical College

Junjie Liu

Central University of Finance and Economics

Youwen Cui

Huazhong University of Science and Technology Tongji Medical College

Xinping Zhang (✉ xpzhang602@hust.edu.cn)

Huazhong University of Science and Technology Tongji Medical College <https://orcid.org/0000-0002-0688-2417>

Research

Keywords: antibiotic consumption, restrictive-prescribing stewardship, primary care, Quality Indicators of European Surveillance of Antimicrobial Consumption (ESAC QIs), interrupted time series analysis

Posted Date: July 9th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-40621/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on September 25th, 2020. See the published version at <https://doi.org/10.1186/s13756-020-00821-7>.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Title

Effects of restrictive-prescribing stewardship on antibiotic consumption in primary care
in China: an interrupted time series analysis, 2012-2017

Authors List:

Xuemei Wang Ph.D¹, Yuqing Tang Ph.D¹, Chenxi Liu Ph.D¹, Junjie Liu Ph.D², Youwen
Cui MM¹, Xinping Zhang Ph.D¹

Affiliation

¹School of Medicine and Health Management, Tongji Medical College, Huazhong
University of Science and Technology, Wuhan, Hubei Province, China

²School of Statistics and Mathematics, Central University of Finance and Economics,
Beijing, China.

Contact information

Corresponding author:

Xinping Zhang

E-mail address: xpzhang602@hust.edu.cn

Other authors:

Xuemi Wang

E-mail address: xm_wang1027@163.com; 466949650@qq.com

Yuqing Tang

E-mail address: 776773386@qq.com

Chenxi Liu

E-mail address: 624078384@qq.com

Junjie Liu

26 E-mail address: 120712614@qq.com

27 Youwen Cui

28 E-mail address: 593721562@qq.com

29

30 **Abstract**

31 **Background:** The overuse of antibiotics has been a major public health problem
32 worldwide, especially in low- and middle- income countries (LMIC). However, there
33 are few policies specific to antibiotic stewardship in primary care and their
34 effectiveness are still unclear. This study aimed to evaluate the effects of a
35 restrictive-prescribing stewardship on antibiotic consumption in primary care so as to
36 provide evidence-based suggestions for prudent use of antibiotics.

37 **Methods:** Monthly antibiotic consumption data were extracted from Hubei Medical
38 Procurement Administrative Agency (HMPA) system from Sept 1, 2012, to Aug 31,
39 2017. Quality Indicators of European Surveillance of Antimicrobial Consumption
40 (ESAC QIs) combined with Anatomical Therapeutic Chemical (ATC) classification
41 codes and DDD per 1000 inhabitants per day (DID) methodology were applied to
42 measure antibiotic consumption. An interrupted time series analysis was performed to
43 evaluate the effects of restrictive-prescribing stewardship on antibiotic consumption.

44 **Results:** Over the entire study period, a significant reduction (declined by 32.58%) was
45 observed in total antibiotic consumption, which declined immediately after
46 intervention (coefficient=-2.4518, P=0.005) and showed a downward trend (coefficient
47 =-0.1193, P=0.017). Specifically, the use of penicillins, cephalosporins and
48 macrolides/lincosamides/streptogramins showed declined trends after intervention
49 (coefficient=-0.0553, P=0.035; coefficient=-0.0294, P=0.037; coefficient=-0.0182,
50 P=0.003, respectively). An immediate decline was also found in the contribution of
51 β -lactamase-sensitive penicillins of total antibiotic use (coefficient=-2.9126, P=0.001).
52 However, an immediate increase in the contribution of third and fourth-generation
53 cephalosporins (coefficient=5.0352, P=0.005) and an ascending trend in the
54 contribution of fluoroquinolones (coefficient=0.0406, P=0.037) were observed after

55 intervention. The stewardship led to an immediate increase in the ratio between broad-
56 and narrow-spectrum antibiotic use (coefficient=1.8747, P=0.001) though they both
57 had a significant downward trend (coefficient=-0.0423, P=0.017; coefficient=-0.0223,
58 P=0.006, respectively). An immediate decline (coefficient=-1.9292, P=0.002) and an
59 ascending trend (coefficient=-0.0815, P=0.018) were also found in the oral antibiotic
60 use after intervention, but no significant changes were observed in the parenteral
61 antibiotic use.

62 **Conclusions:** Restrictive-prescribing stewardship in primary care was effective in
63 reducing total antibiotic consumption, especially use of penicillins, cephalosporins and
64 macrolides/lincosamides/streptogramins. However, the intervention effects were mixed.
65 Stronger administrative regulation focusing on specific antibiotics, such as the third
66 and fourth-generation cephalosporins, fluoroquinolones, broad-spectrum antibiotics
67 and parenteral antibiotics, is in urgent need in the future.

68

69 **Keywords:** antibiotic consumption; restrictive-prescribing stewardship; primary care;
70 Quality Indicators of European Surveillance of Antimicrobial Consumption (ESAC QIs);
71 interrupted time series analysis

72

73 **1. Introduction**

74 Antimicrobial resistance (AMR) has been increasingly concerned as a major public
75 health problem worldwide, leading to longer hospital stays, higher medical costs and
76 increased mortality [1; 2]. It was estimated that approximately 25,000 deaths in Europe,
77 and 23,000 deaths in the USA were caused by AMR each year[3]. The health care costs
78 resulted from antibiotic-resistant infections were as high as \$20 billion and the lost
79 productivity was estimated to be \$35 billion per year in the US[4]. If no actions are
80 taken, up to 10 million additional lives would be lost and the total economic burden
81 would reach \$100 trillion by 2050 [5].

82 The intensive use of antibiotics has been regarded as a main driver of AMR and
83 the unnecessary use further worsened such situation [1; 6]. The global antibiotic
84 consumption increased by 65%between 2000 and 2015, which was primarily driven by
85 increased consumption in low- and middle-income countries (LMICs)[7]. It was
86 reported that 30-50% of antibiotics prescribed were unnecessary or suboptimal [8]. It
87 has been widely recognized that primary care should take main responsibilities because
88 the most majority of antibiotic consumption tend to occur in primary care, which has
89 been demonstrated by the fact that approximately half of patients attending primary
90 care received at least one antibiotic in LMICs [9].

91 There are few policies specific to antibiotic stewardship in primary care and little
92 is known about the practical effectiveness. Although previous studies have conducted
93 some small-sale interventions to regulate antibiotic overuse in primary care, but the
94 effects are mixed and confused. As examples, online evidence-based feedbacks
95 effectively reduced antibiotic prescribing from 37.4% to 28.1%in patients with
96 suspected respiratory tract infections (RTIs) attending primary care [10]. Similarly, a
97 weekly prospective audit and feedback in three community facilities brought about a 25%

98 immediate reduction in all antibiotic prescriptions after conducting the antibiotic
99 stewardship and a continuous 5% decrease over the entire intervention [11]. However,
100 other studies showed inconsistent findings. A systematic review summarizing
101 educational interventions to improve antibiotic prescribing showed that 62% of studies
102 in primary care reported positive results for all measured outcomes, including total
103 antibiotic prescription, prescribing attitudes and behaviors, and etc.; 30% reported
104 partial results that were not statistically significant and the remaining studies failed to
105 report any significant improvements [12]. Further high-level evidence is needed to
106 instruct intervention strategies in regulating antibiotic consumption in primary care.

107 Previous antibiotic stewardship programs in China mainly focus on secondary and
108 tertiary hospitals, which have achieved significant improvements [13]. However, very
109 few detailed or targeted policies are specific to antibiotic consumption in primary care,
110 leading to a relatively poor regulation efficiency on them. For instance, an increasing
111 trend was observed in the overall antibiotic consumption in urban primary healthcare
112 centers in Shandong province of China, revealing an urgent need for strengthened
113 regulation on antibiotic use in primary care [14]. Therefore, it is necessary to evaluate
114 the intervention effects on antibiotic use in primary care, especially on some specific
115 antibiotics, so as to supplement more targeted evidence.

116 A restrictive-prescribing stewardship with specified administrative regulation was
117 issued in 2014 in Hubei province of China, aiming at further promote prudent use of
118 antibiotics [15]. This administrative regulation put forward detailed restriction specific
119 to antibiotic prescribing in primary care, featured as concretely restricting the type,
120 dose, form, route of administration on antibiotics. This study aimed to evaluate the
121 effects of this restrictive-prescribing stewardship on antibiotic consumption in primary
122 care, especially with advantage of an internationally comparable methodology of

123 Quality Indicators of European Surveillance of Antimicrobial Consumption (ESAC
124 QIs)[16]. The findings will fill the gaps in literature, especially supplementing
125 comparable evidence on the antibiotic stewardship in primary care, so as to further
126 promote prudent use of antibiotics in primary care.

127 **2. Methods**

128 **2.1 Settings and data sources**

129 This study was conducted in Hubei province, central China. Hubei has a population of
130 over 61 million and covers an area of 185,900 km². Its per capita gross domestic
131 product (GDP) is 60198.68 yuan (\$8915.95 USD), ranking in the middle range of all
132 provinces. The disposable income for rural residents and urban residents is 13,812.09
133 yuan (\$2,059.38 USD) and 31,889.42 yuan (\$4,754.71 USD) respectively (2017). There
134 are 36,323 healthcare institutions in Hubei, among which 34,742 are primary care
135 institutions, including state-owned community or township centers[17].

136 Data used in this study were extracted from the Hubei Medical Procurement
137 Administrative Agency (HMPA) system, which provided a specialized and reliable
138 source on the medicine consumption, including antibiotics[18]. The database is
139 targeted for primary care institutions, and monthly procurement data are recorded and
140 updated. According to the requirements of HMPA, primary care institutions are allowed
141 to stock and dispense medicines listed in the Essential Medicines List (EML) from its
142 procurement platform, except for few supplementary medicines, e.g. emergency
143 medicine. All the valid procurement records of antibiotics between September 2012
144 and August 2017 (except for few blank procurement records) were collected for our
145 study.

146 **2.2 Study design**

147 A restrictive-prescribing stewardship specific to antibiotics in primary care was

148 developed in November 2014 and formally implemented since December 2014 in
149 Hubei Province. The core objective of this policy was to strengthen the prudent use of
150 antibiotics. Restrict regulation on the antibiotic type, dose, form and route of
151 administration were primary measures of this restrictive-prescribing stewardship. To
152 better guarantee the implementation effects, local health commission were required to
153 take responsibilities for the stewardship, supervision and evaluation on this program.
154 The local healthcare institutions were also demanded to manage the antibiotic
155 procurement, storage, usage, supervision and feedback[15].

156 ***2.3 Measurement of antibiotic consumption***

157 The Anatomical Therapeutic Chemical (ATC) classification codes were used to
158 categorize medicines, and procurement records of J01 (antibiotics for systemic use)
159 were extracted for the purpose of this study[19]. Defined daily dose (DDD) was used to
160 measure the volume of antibiotics according to the WHO Collaborating Centre for
161 Drug Statistics Methodology[20]. DDD equivalence per package (DPP) was expressed
162 in DDD units $[(\text{unit strength} \times \text{pack size})/\text{DDD}]$. The summed DPPs of all-inclusive
163 products formed the total volume for each group of antibiotic consumption (DDDs). To
164 strengthen the comparability of antibiotic use, the DDD per 1000 inhabitants per day
165 (DID) was eventually transformed to calculate antibiotic consumption.

166 To provide drug-specific insight in measuring antibiotic consumption and trigger
167 action to improve antibiotic use, quality indicators (QIs) proposed by European
168 Surveillance of Antimicrobial Consumption (ESAC) were used to measure antibiotic
169 use, which has become an internationally comparable methodology[16; 21]. In this
170 study, 10 ESAC QIs were selected into analysis and the remaining 2 ESAC QIs were
171 not included because they were not suitable for the statistical methodology in this
172 study. In addition, 4 local QIs were developed after considering the policy context in

173 China (Table 1).

174 *[Table 1 could be cited here]*

175 **2.4 Statistical analysis**

176 Regular, evenly spaced intervals are appropriate for a segmented regression analysis to
177 evaluate the effect of intervention[22]. In this research, monthly antibiotic
178 consumption from Sept 1, 2012, to Aug 31, 2017 was applied as analytical unites.

179 To estimate the effect of restrictive prescribing stewardship on antibiotic use, the
180 following segmented linear regression model was applied [23]:

$$181 Y_t = \beta_0 + \beta_1 * Time_t + \beta_2 * Intervention_t + \beta_3 * Time \text{ after } intervention_t + \\ 182 \beta_4 * \sin(2 \Pi Time_t / 12) + \beta_5 * \cos(2 \Pi Time_t / 12) \varepsilon_t$$

183 As two key parameters in the segmented linear regression, level and trend define
184 each segment of a time series. The level is the value of the series at the beginning of a
185 given time interval, while the trend is the rate of change of the intervention measure.

186 Here, Y_t is the average number of antibiotic use in month t ; Time is a continuous
187 variable indicating time in months at time t from the start of observation; intervention is
188 an indicator for $Time_t$ occurring before (intervention=0) or after (intervention=1) the
189 cap, which was implemented at month 28 (December, 2014) in the series; and
190 $Time \text{ after } intervention_t$ is a continuous variable counting the number of months
191 after the intervention at time t , coded 0 before the cap and added by 1 continuously after
192 the cap. The coefficients β_0 and β_1 respectively estimate the baseline level of outcome
193 at time zero, and the change that occurs with each month before the intervention; β_2 and
194 β_3 respectively estimate the level change in the average monthly number of antibiotic
195 use immediately after the intervention, and the trend change of indicators after the cap,
196 compared with the monthly trend before the cap; The sum of $\beta_1 + \beta_3$ is the post
197 intervention slope. β_4 and β_5 were used to adjust for a potential seasonality effect [24].
198 The error term ε_t represents the random variable not explained by the model at time t .

199 The Durbin-Watson test was used to check for autocorrelation.

200 All statistical analyses above were performed using STATA version 12.0 (STATA
201 Corp, College Station, TX, USA) and $P < 0.05$ was considered statistically significant.

202 **3. Results**

203 **3.1 Overall antibiotic consumption over the entire study period**

204 Over the entire study period, the total antibiotic consumption (J01) in primary care in
205 Hubei province declined from 11.02 DID to 7.43 DID (declined by 32.58%). For
206 penicillins (J01C) and cephalosporins (J01D), the consumption respectively decreased
207 from 5.01 DID to 2.64 DID (declined by 52.69%) and 3.08 DID to 2.54 DID (declined
208 by 17.53%). For quinolones (J01M) and
209 macrolides/lincosamides/streptogramins (J01F), the consumption declined from 1.05
210 DID to 0.71 DID (declined by 32.38%) and 1.03 DID to 0.82 DID (declined by 20.39%)
211 respectively (Fig.1).

212 *[Figure 1 could be cited here]*

213 The relative contributions of β -lactamase-sensitive penicillins (J01CE) of total
214 antibiotic use declined from 7.78% to 4.12% (declined by 3.66%). However, the
215 relative contributions of penicillins with β -lactamase inhibitors (J01CR), third and
216 fourth generation cephalosporins (J01DD/DE) and fluoroquinolones (J01MA) of total
217 antibiotic use respectively increased from 3.08% to 6.19%, 14.43% to 18.13%, and
218 9.51% to 9.56% (increased by 3.11%, 3.70% and 0.05%, respectively) (Fig.2).

219 *[Figure 2 could be cited here]*

220 The consumption of broad-spectrum antibiotics and narrow-spectrum antibiotics
221 respectively declined from 3.82 DID to 3.20 DID (declined by 16.23%) and 1.51 DID
222 to 0.68 DID (declined by 54.97%). However, the ratio between broad- and
223 narrow-spectrum antibiotic consumption increased from 2.51 to 5.09 (Fig.3).

224

[Figure 3 could be cited here]

225 The consumption of oral antibiotics and parenteral antibiotics respectively
226 declined from 5.84 DID to 3.33 DID (declined by 42.98%), and 5.18 DID to 4.09 DID
227 (21.04%). The average decline of oral antibiotic consumption was greater than that of
228 parenteral antibiotics over the entire study period (Fig.4).

229

[Figure 4 could be cited here]

230

3.2 Effects of restrictive-prescribing stewardship on antibiotic consumption

231 Before implementing restrictive-prescribing stewardship, the consumption of total
232 antibiotics(J01) showed an ascending trend that was not statistically significant
233 (coefficient=0.0237, P=0.554), while the consumption declined immediately after
234 intervention (coefficient=-2.4518, P=0.005) and had a significant downward trend
235 (coefficient=-0.1193,P=0.017).The consumption of penicillins (J01C),
236 macrolides/lincosamides/streptogramins (J01F), quinolones (J01M) declined
237 immediately after intervention (coefficient=-1.9109, P<0.001; coefficient=-0.2248,
238 P=0.030; coefficient=-0.2019, P=0.019, respectively), and the consumption of
239 penicillins (J01C), cephalosporins (J01D) and macrolides/lincosamides/streptogramins
240 (J01F) showed declined trends after intervention (coefficient=-0.0553, P=0.035;
241 coefficient=-0.0294, P=0.037; coefficient=-0.0182, P=0.003, respectively).

242

243 The restrictive-prescribing stewardship was associated with an immediate decline
244 in the contribution of β -lactamase-sensitive penicillins (J01CE) of total antibiotic use
245 (coefficient=-2.9126, P=0.001). However, an immediate increase was observed in the
246 contribution of third and fourth-generation cephalosporins (J01DD/DE) of total
247 antibiotic use(coefficient=5.0352, P=0.005), and an ascending trend was found in the
248 contribution of fluoroquinolones (J01MA) of total antibiotic use (coefficient=0.0406,
P=0.037) after intervention.

249 The stewardship also led to an immediate increase in the ratio between broad- and
250 narrow-spectrum antibiotic use (coefficient=1.8747, P=0.001) though they both had a
251 significant downward trend (coefficient=-0.0423, P=0.017; coefficient=-0.0223,
252 P=0.006, respectively).

253 Finally, the stewardship was associated with an immediate decline in the
254 consumption of oral antibiotics (coefficient=-1.9292, P=0.002) and a continuous
255 downward trend (coefficient=-0.0815, P=0.018). However, no significant changes were
256 found in the consumption of parenteral antibiotics after intervention (Table 2).

257 *[Table 2 could be cited here]*

258 **4. Discussion**

259 **4.1 Summary of main findings**

260 This study confirmed that the restrictive-prescribing stewardship achieved positive
261 effects in declining total antibiotic use, especially the use of penicillins, cephalosporins
262 and macrolides/lincosamides/streptogramins. However, the intervention effects on the
263 consumption of some other antibiotics were mixed, which deserved more attention and
264 discussion.

265 **4.2 Strengths and limitations of the study**

266 To the best of our knowledge, it was the first study that attempted to evaluate the effects
267 of restrictive-prescribing stewardship on antibiotic consumption in primary care, with
268 advantage of drug-specific quality indicators of ESAC (ESAC QIs) combined with an
269 interrupted time series design and DID methodology.

270 There are several limitations in this study. First, not all antibiotics consumed in
271 primary care institutions were included in this study. The data of non-prescribed
272 antibiotic use (e.g. self-medication at home or over-the-counter) and prescriptions in
273 private primary care facilities were difficult to access. Second, the data used in this

274 study were procurement data instead of directly extracting from the actual medicine use
275 in each institution. However, the procurement data were based on the current practical
276 consumption, which was approximately equivalent to the actual medicine use.

277 ***4.3 Comparison with existing literature***

278 This study confirmed that the restrictive-prescribing stewardship was associated with a
279 significant reduction in total antibiotic consumption, especially the use of penicillins,
280 cephalosporins and macrolides/lincosamides/streptogramins, which was consistent
281 with some previous findings. Borde J Pet al.[25] found that the total antibiotic use
282 declined by 11% after implementing anintensified antibiotic stewardship in community
283 hospital in Germany, and the use of cephalosporins declined by 33%.Borde J P et
284 al.[26]discovered that the use of macrolides/ clindamycin declined by 24.4% after
285 intervention in a tertiary academic hospital.Regarding the use of penicillins, there were
286 some different findings in other studies.For instance, Tavares M et al.[27]found that a
287 significant increase was discovered in the use of penicillins, followed by a
288 monthlydecrease in slope after implementing an audit and feedback antibiotic
289 stewardship. It can be seen that the restrictive prescribing stewardship in this study
290 achieved better intervention results than other studies, especially in regulating the use
291 of penicillins.Regarding the consumption of quinolones, an immediate decline was
292 observed after intervention but no significant effects were observed afterwards in this
293 study, which was consistent with a study by McNulty C et al. [28]that the quinolone use
294 in the intervention group was lower than that in the control group, but a slight increase
295 was then observed though there was no statistical significance. Cheng AC et al.[29]
296 found that educational initiatives made no substantial progress in reducing quinolone
297 use in primary care in Australia, but a decline of 30% was achieved after introducing a
298 narrowed list of indications forquinolones, which confirmed that a

299 stronger administrative regulation specific to antibiotic categories is necessary.

300 Judging from the relative contributions of total antibiotic use, an immediate
301 decline was found in the contribution of β -lactamase-sensitive penicillins of total
302 antibiotic use, while an immediate increase was observed in the contribution of third
303 and fourth-generation cephalosporins and an ascending trend was found in the
304 contribution of fluoroquinolones after intervention. Similar findings were discovered in
305 previous studies. For instance, Ruiz J et al.[30] found that the consumption of
306 β -lactamase-sensitive penicillins significantly declined by 34.50 DDD per 100 patients
307 per day after implementing audit and feedback antimicrobial stewardship. Regarding
308 the contribution of third and fourth-generation cephalosporins and fluoroquinolones of
309 total antibiotic use, it has been recognized that the third generation cephalosporins and
310 fluoroquinolones were frequently prescribed for common infections, which is usually
311 difficult to largely reduce their prescriptions accounting for total
312 antibiotics[31]. Moreover, Jindai K et al. [32] discovered a significant initial reduction
313 on fluoroquinolone prescribing rate but the reduction was not sustained later, which put
314 forward requirement on sustainable strategies.

315 It is well-known that broad-spectrum antibiotics are prescribed instead of
316 narrow-spectrum antibiotics in many cases [33]. Regulating the overuse of
317 broad-spectrum antibiotics can make great significance in minimizing resistance for
318 patients. This study revealed that restrictive-prescribing stewardship led to a significant
319 downward trend in broad- and narrow-spectrum antibiotic use, but an immediate
320 increase was observed in the ratio between them. Hernandez-Santiago V et al.
321 [34] found that the broad-spectrum antibiotic prescription achieved a significant
322 sustained reduction after introducing an intervention combining guidelines, education
323 and feedback in Scotland. Kuyvenhoven M et al. [35] pointed out that a decrease of

324 narrow-spectrum antibiotic use has been accompanied by an increase of
325 broad-spectrum antibiotics in America. Aabenhus R et al.[36] also found that the
326 consumption of broad-spectrum antibiotics increased while narrow-spectrum
327 antibiotics declined in primary care in Denmark. These also demonstrated that the ratio
328 between broad- and narrow-spectrum antibiotic use is difficult to decline as the
329 consumption of broad-spectrum antibiotics over the last decades has always occupied a
330 major proportion of total antibiotics and presented a dramatical increase[33].

331 Overuse of injections has become common concerns in many LMICs and may
332 result in unexpected outcomes and resource wastage[37]. The restrictive-prescribing
333 stewardship failed to make significant progress in regulating parenteral antibiotic use,
334 though significant decline were found in the consumption of oral antibiotics. However,
335 Hersh AL et al.[38] found a 24% decline in parenteral antibiotic use after implementing
336 an outpatient parenteral antibiotic therapy (OPAT) stewardship program. The different
337 intervention effects may attribute to whether the stewardship program was specific to
338 parenteral antibiotics. The reason for the overuse of injections lies in a wide belief in
339 many cultures that injection is a quite powerful method for health, so patients tend to
340 prefer injections to oral medicines [39]. In addition, physicians are more likely to
341 prescribe injections to satisfy patients' demand and earn a higher salary due to a more
342 expensive price on injections [39].

343 ***4.4 Policy implications***

344 It is a well-known fact that overuse of antibiotics is directly related to AMR and to an
345 increase in morbidity and mortality [30]. Restrictive-prescribing stewardship could
346 play an essential role in regulating overuse of antibiotics from the whole. However,
347 regarding the use of antibiotics whose intervention effects were limited in this study,
348 for instance, broad-spectrum antibiotics especially the third and fourth-generation

349 cephalosporins, fluoroquinolones and etc., a stronger antibiotic stewardship is needed.
350 Future stewardship programs focusing on individual antibiotics combined with
351 multi-faceted interventions should be strengthened to achieve sustainable
352 improvement.

353 **5. Conclusion**

354 Restrictive-prescribing stewardship in primary care achieved significant effects in
355 reducing total antibiotic consumption, especially use of penicillins, cephalosporins and
356 macrolides/lincosamides/streptogramins. However, the effects on other antibiotics
357 were mixed. Stronger administrative regulation is necessary to focus on drug-specific
358 antibiotics, such as the third and fourth-generation cephalosporins, fluoroquinolones,
359 broad-spectrum antibiotics and parenteral antibiotics. Future studies are warranted to
360 explore the potential influencing factors of limited effects in those antibiotics and
361 accordingly design a stronger and more targeted antibiotic stewardship strategy.

362

363 **List of abbreviations**

364 ATC: Anatomical Therapeutic Chemical classification

365 DID: DDD per 1000 inhabitants per day

366 ESAC QIs: Quality Indicators of European Surveillance of Antimicrobial Consumption

367 J01: antibiotics for systemic use

368 J01C: penicillins

369 J01D: cephalosporins

370 J01F: macrolides/lincosamides/streptogramins

371 J01M: quinolones

372 J01CE: β -lactamase-sensitive penicillins

373 J01CR: penicillins with β -lactamase inhibitors

374 J01DD/DE: third and fourth generation cephalosporins

375 J01MA: fluoroquinolones

376 J01DC:second generation cephalosporins

377 J01FA01:erythromycin

378 J01DB:first generation cephalosporins

379 CI: confidence intervals

380 DW: Durbin-Watson

381

382 ***Declarations***

383 ***Ethics approval and consent to participate***

384 A prior abstract about part of the findings was submitted for the 2019 Lancet–CAMS
385 Health Conference held in China, and it was accepted and printed on the conference
386 brochure and posters[40]. However, the full manuscript has never been submitted or
387 published in the Lancet journal or elsewhere. According to the ethics and consent, we
388 have cited the published abstract in this article.

389 ***Consent for publication***

390 Consent for publication was obtained from each participant prior to the survey, and the
391 formal full manuscript was also allowed for publication in other journals by the 2019
392 Lancet–CAMS Health Conference.

393 ***Availability of data and materials***

394 The original data used in this study were extracted from the Hubei Medical Procurement
395 Administrative System(HMPAS), which is a publicly available platform.

396 ***Competing interests***

397 The authors declare no conflict of interest.

398 ***Funding***

399 This study was funded by the National Natural Science Foundation of China Youth
400 Fund (grant number 71704058).

401 *Authors' contributions*

402 XW contributed to the study design, data analysis, and drafting of the manuscript. YT
403 was involved in the conception and revision of the manuscript. CL and JL participated
404 in the revision of the manuscript. YC participated in the extraction and interpretation of
405 the data. XZ and YT made substantial contributions to the conception, design, and
406 revision of the manuscript. All authors have seen and approved the final version of this
407 article for publication.

408 *Acknowledgements*

409 The authors would like to sincerely thank the help and support provided by members
410 involved in this article, especially the valuable and professional suggestions on poster
411 abstract by the editors of 2019 Lancet–CAMS Health Conference.

412

413 *References*

414 [1] Goossens H, Ferech M, Stichele RV, Elseviers M. Outpatient antibiotic use in
415 Europe and association with resistance: a cross-national database study. *The Lancet*.
416 2005; 365(9459): 579-587.

417 [2] Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N,
418 Vlieghe E, Hara GL, Gould IM, Goossens H, Greko C, So AD, Bigdeli M, Tomson G,
419 Woodhouse W, Ombaka E, Peralta AQ, Qamar FN, Mir F, Kariuki S, Bhutta ZA,
420 Coates A, Bergstrom R, Wright GD, Brown ED, Cars O. Antibiotic resistance—the
421 need for global solutions. *Lancet Infect. Dis.* 2013; 13(12): 1057-1098.

422 [3] Sabtu N, Enoch DA, Brown NM. Antibiotic resistance: what, why, where, when and
423 how?. *BRIT MED BULL.* 2015; 116:105-113.

- 424 [4]Golkar Z, Bagasra O, Pace DG. Bacteriophage therapy: a potential solution for the
425 antibiotic resistance crisis. *J INFECT DEV COUNTR*. 2014; 8(2): 129-136.
- 426 [5]Jasovský D, Littmann J, Zorzet A, Cars O. Antimicrobial resistance-a threat to the
427 world's sustainable development.*UPSALA J MED SCI*. 2016; 121(3): 159-164.
- 428 [6] Malone SM, Seigel N, Newland JG, Saito JM, McKay VR. Understanding
429 antibiotic prophylaxis prescribing in pediatric surgical specialties. *Infect Control Hosp*
430 *Epidemiol*. 2020: 1-6.
- 431 [7]Klein EY, Van Boeckel TP, Martinez EM, Panta S, Gandraa S, Levine SA,
432 Goossens H, Laxminarayan R. Global increase and geographic convergence in
433 antibiotic consumption between 2000 and 2015. *Proc Natl Acad Sci U S A*; 2018,
434 115(15): E3463-E3470.
- 435 [8] Bansal R, Jain A, Goyal M, Singh T, Sood H, Malviya HS. Antibiotic abuse during
436 endodontic treatment: A contributing factor to antibiotic resistance. *J Family Med Prim*
437 *Care*. 2019; 8(11): 3518-3524.
- 438 [9]Sulis G, Adam P, Nafade V, Gore G, Daniels B, A. Daftary A, Das J, Gandra S, Pai
439 M. Antibiotic prescription practices in primary care in low- and middle-income
440 countries: A systematic review and meta-analysis. *PLoS Med*. 2020; 17(6): e1003139.
- 441 [10]Urbiztondo I, Bjerrum L, Caballero L, Suarez MA, Olinisky M, Córdoba G.
442 Decreasing Inappropriate Use of Antibiotics in Primary Care in Four Countries in
443 South America—Cluster Randomized Controlled Trial. *J Antibiot*. 2017, 6(38): 1-10.
- 444 [11]Doernberg SB, Dudas V, Trivedi KK. Implementation of an antimicrobial
445 stewardship program targeting residents with urinary tract infections in three
446 community long-term care facilities: a quasi-experimental study using time-series
447 analysis. *Antimicrob Resist Infect Control*. 2015; 4: 54.
- 448 [12] Roque F, Herdeiro MT, Soares S, Rodrigues AT, Breitenfeld L, Figueiras A.

449 Educational interventions to improve prescription and dispensing of antibiotics: a
450 systematic review. BMC Public Health. 2014; 14: 1276.

451 [13] Bao L, Peng R, Wang Y, Ma R, Ren X, Meng W, Sun F, Fang J, Chen P, Wang Y,
452 Chen Q, Cai J, Jin J, Guo J, Yang S, Mo X, Zhang E, Zhang Y, Lu Z, Chen B, Yue X,
453 Zhu M, Wang Y, Li X, Bian Y, Kong S, Pan W, Ding Q, Cao J, Liu R, Chen N, Huang X,
454 B A, Lyu H. Significant reduction of antibiotic consumption and patients' costs after an
455 action plan in China, 2010-2014. PloS one. 2015; 10(3): e0118868.

456 [14] Yin J, Li Q, Sun Q. Antibiotic consumption in Shandong Province, China: an
457 analysis of provincial pharmaceutical centralized bidding procurement data at public
458 healthcare institutions, 2012-16. J Antimicrob Chemother. 2018; 73: 814-820.

459 [15] Health Commission of Hubei Province. Notice on the issuance of the
460 "Administrative Measures for the Provision and Use of Essential Medicines in Medical
461 and Health Institutions in Hubei
462 Province".<http://www.hbjycg.com:83/eWebEditor/uploadfile/20150205165603903.pdf>
463 f. Accessed 8 April 2019.

464 [16] Coenen S, Ferech M, Haaijer-Ruskamp FM, Butler CC, Stichele RHV, Verheij
465 TJM, Monnet DL, Goossens H, the ESAC Project Group. European Surveillance of
466 Antimicrobial Consumption (ESAC): quality indicators for outpatient antibiotic use in
467 Europe. Qual Saf Health Care. 2007;16(6): 440-445.

468 [17] Hubei Provincial Bureau of Statistics. Statistical
469 Yearbook.<http://tjj.hubei.gov.cn/tjsj/sjkscx/tjn/qstjnj/>. Accessed 23 April 2019.

470 [18] Hubei Medical Procurement Administrative Agency (HMPA). Centralized online
471 drug procurement in primary care institutions in Hubei
472 Province.<http://www.hbjycg.com:83/HomePage/ShowList.aspx?CatalogId=40>.
473 Accessed 5 April 2019.

- 474 [19] WHO. WHO methodology for a global programme on surveillance of
475 antimicrobial consumption.
476 https://www.who.int/medicines/areas/rational_use/WHO_AMCsurveillance_1.0.pdf.
477 Accessed 15 April 2019.
- 478 [20] WHOCC. ATC/DDD Index and
479 Guidelines.https://www.whocc.no/atc_ddd_index/. Accessed 8 April 2019.
- 480 [21] Velden AW, Roukens M, Garde EV, Lourens M, Natsch S. Usefulness of quality
481 indicators for antibiotic use: case study for the Netherlands. *Int J Qual Health Care*.
482 2016; 28(6): 838-842.
- 483 [22]Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression
484 analysis of interrupted time series studies in medication use research.*J CLIN PHARM*
485 *THER*. 2002; 27(4): 299-309.
- 486 [23]Tang Y, Liu C, Zhang Z, Zhang X. Effects of prescription restrictive interventions
487 on antibiotic procurement in primary care settings: a controlled interrupted time series
488 study in China. *Cost Eff Resour Alloc*. 2018; 16:1.
- 489 [24]Chandy SJ, Naik GS, Charles R, Jeyaseelan V, Naumova EN, Thomas K, Lundborg
490 CS. The impact of policy guidelines on hospital antibiotic use over a decade: a
491 segmented time series analysis. *PloS one*. 2014; 9(3): e92206.
- 492 [25]Borde JP, Litterst S, Ruhnke M, Feik R, Hu'bnner J, deWith K, Kaier K, Kern WV.
493 Implementing an intensified antibiotic stewardship programme targeting cephalosporin
494 and fluoroquinolone use in a 200-bed community hospital in Germany. *Infection*. 2015;
495 43(1): 45-50.
- 496 [26]Borde JP, Kaier K, Steib-Bauert M, Vach W, Geibel-Zehender A, Busch H, Bertz H,
497 Hug M, With K, Kern WV. Feasibility and impact of an intensified antibiotic
498 stewardship programme targeting cephalosporin and fluoroquinolone use in a tertiary

499 care university medical center. BMC INFECT DIS. 2014; 14: 201.

500 [27]Tavares M, Carvalho AC, Almeida JP, Andrade P, RicardoSão-Simão, Soares P,
501 Alves C, Pinto R, Fontanet A, Watier L. Implementation and impact of an audit and
502 feedback antimicrobial stewardship intervention in the orthopaedics department of a
503 tertiary-care hospital: a controlled interrupted time series study. Int. J. Antimicrob.
504 Agents. 2018; 51(6): 925-931.

505 [28]McNulty C, Hawking M, Lecky D, Jones L, Owens R, Charlett A, Butler C, Moore
506 P, Francis N. Effects of primary care antimicrobial stewardship outreach on antibiotic
507 use by general practice staff: pragmatic randomized controlled trial of the TARGET
508 antibiotics workshop. J Antimicrob Chemotherapy. 2018; 73(5): 1423-1432.

509 [29]Cheng AC, Turnidge J, Collignon P, Looke D, Barton M, Gottlieb T. Control of
510 fluoroquinolone resistance through successful regulation, Australia. Emerg Infect Dis
511 2012; 18: 1453–60.

512 [30]Ruiz J, Ramirez P, Gordon M, Villarreal E, Frassetto J, Poveda-Andres JL,
513 Salavert-Lletí M, Catellanos A. Antimicrobial stewardship programme in critical care
514 medicine: A prospective interventional study. Med Intensiva. 2018, 42(5): 266-273.

515 [31] Wang S, Pulcin C, Rabaud C, Boivin JM, Birgé J. Inventory of antibiotic
516 stewardship programs in general practice in France and abroad. MED MALADIES
517 INFECT. 2015; 45: 111-123.

518 [32] Jindai K, Goto M, MacKay K, Forrest GN, Musuuza J, PhD6, Safdar N, Pfeiffer
519 CD. Improving fluoroquinolone use in the outpatient setting using a patient safety
520 initiative. Infect Control Hosp Epidemiol. 2018; 39: 1108–1111.

521 [33]Kourlaba G, Gkranaki E, Kourkouni E, Mavrogeorgos G, Zaoutis T.
522 Antibiotic prescribing and expenditures in outpatient adults in Greece, 2010 to 2013:
523 evidence from real-world practice. Eurosurveillance. 2016; 21(26): 1-9.

524 [34]Hernandezsantiago V, Marwick C, Patton A, Davey PG, Donnan PT, Guthrie B.
525 Time series analysis of the impact of an intervention in Tayside, Scotland to reduce
526 primary care broad-spectrum antimicrobial use. *J Antimicrob Chemother.* 2015; 70(8):
527 2397-2404.

528 [35]Kuyvenhoven M, Van Essen GV, Schellevis F, Verheij T. Management of upper
529 respiratory tract infections in Dutch general practice: antibiotic prescribing rates and
530 incidences in 1987 and 2001. *Fam Pract.* 2006; 23(2): 175-179.

531 [36]Aabenhus R, Siersma V, Hansen MP, Bjerrum L. Antibiotic prescribing in Danish
532 general practice 2004–13. *J Antimicrob Chemother.* 2016; 71(8): 2286-2294.

533 [37] Soleymani F, Rashidian A, Hosseini M, Dinarvand R, Kebriaeezade A, Abdollahi
534 M. Effectiveness of audit and feedback in addressing over prescribing of antibiotics and
535 injectable medicines in a middle-income country: an RCT. *DARU.* 2019; 27(1):
536 101-109.

537 [38] Hersh AL, Olson J, Stockmann C, Thorell EA, Knackstedt ED, Esquibel L,
538 Sanderson S, Pavia AT. Impact of Antimicrobial Stewardship for Pediatric Outpatient
539 Parenteral Antibiotic Therapy. *J PEDIAT INF DIS SOC.* 2018; 7(2): e34-e36.

540 [39] Cheraghali AM, Solemani F, Behmanesh Y, Habibipour F, Ismaeilzadeh A, Nikfar
541 S, Rahimi W. Physicians` Attitude Toward Injectable Medicine. *J PharmacolToxicol,*
542 2006, 1(1): 33-39.

543 [40] Wang X, Tang Y, Liu C, Liu J, Cui Y, Zhang X. Effects of restrictive prescribing on
544 antibiotic consumption in primary care in China, 2012–17: an interrupted time-series
545 analysis. *The Lancet.* 2019 [Poster Abstracts].

546
547
548

Table 1. Quality indicators of measuring antibiotic consumption in this study

NO.	Quality indicators
ESAC QIs 1-5 are the use of relevant antibiotics (expressed in DID):	
1	<i>total use of J01</i>
2	<i>use of penicillins (J01C)</i>
3	<i>use of cephalosporins (J01D)</i>
4	<i>use of macrolides/lincosamides/streptogramins (J01F)</i>
5	<i>use of quinolones (J01M).</i>
ESAC QIs 6-9 are the relative contributions (% of total J01 use) of:	
6	<i>β-lactamase-sensitive penicillins (J01CE)</i>
7	<i>combinations of penicillins with β-lactamase inhibitors (J01CR)</i>
8	<i>third and fourth generation cephalosporins (J01DD/DE)</i>
9	<i>fluoroquinolones (J01MA)</i>
ESAC QI 10 is the ratio between broad- and narrow-spectrum antibiotics:	
10	$(J01CR+J01DC+J01DD+J01F \text{ (minus } J01FA01))/(J01CE+J01DB+J01FA01)$
QIs 11-14 are adapted according to the policy context in China (expressed in DID):	
11	<i>use of broad-spectrum antibiotics</i>
12	<i>use of narrow-spectrum antibiotics</i>
13	<i>use of oral antibiotics</i>
14	<i>use of parenteral antibiotic</i>

551

552

553

554 **Table 2.** The segmented regression analysis of stewardship on antibiotic consumption

	Baseline level (95% CI)	Baseline trend (95% CI)	Level change after intervention (95% CI)	Trend change after intervention (95% CI)	DW
<i>Use of relevant antibiotics (expressed in DID)</i>					
J01	10.7777*** (9.51, 12.05)	0.0237 (-0.06, 0.10)	-2.4518** (-4.14, -0.76)	-0.1193* (-0.22, -0.02)	2.0572
J01C	4.8920*** (4.22, 5.56)	0.0124 (-0.03, 0.05)	-1.9109*** (-2.80, -1.02)	-0.0553* (-0.11, -0.00)	1.9703
J01D	3.1150*** (2.75, 3.48)	-0.0015 (-0.02, 0.02)	-0.0262 (-0.51, 0.45)	-0.0294* (-0.06, -0.00)	2.2194

J01F	0.9053*** (0.75, 1.06)	0.0099* (0.00, 0.02)	-0.2248* (-0.43, -0.02)	-0.0182** (-0.03, -0.01)	1.9409
J01M	1.0594*** (0.93, 1.19)	-0.0005 (-0.01, 0.01)	-0.2019* (-0.37, -0.03)	-0.0077 (-0.02, 0.00)	2.0270

Relative contributions (% of total J01 use)

J01CE	7.2141*** (5.86, 8.57)	0.0271 (-0.06, 0.11)	-2.9126** (-4.55, -1.27)	-0.0825 (-0.19, 0.03)	2.0439
J01CR	2.6349*** (1.71, 3.56)	0.0312 (-0.03, 0.09)	1.2010 (-0.01, 2.41)	0.0618 (-0.01, 0.13)	1.9534
J01DD/DE	16.2036*** (13.55, 18.85)	-0.1312 (-0.30, 0.03)	5.0352** (1.55, 8.52)	0.1543(-0.05, 0.36)	1.9815
J01MA	9.7988*** (9.31, 10.29)	-0.0246 (-0.05, 0.01)	0.2156 (-0.42, 0.85)	0.0406* (0.00, 0.08)	1.8880

Use of Broad- and narrow-spectrum antibiotics (expressed in DID)

Broad	3.6089*** (3.16, 4.06)	0.0148 (-0.01, 0.04)	-0.1212 (-0.72, 0.48)	-0.0423* (-0.08, -0.01)	2.2142
Narrow	1.4481*** (1.24, 1.65)	0.0055 (-0.01, 0.02)	-0.6449*** (-0.92, -0.37)	-0.0223** (-0.04, -0.01)	1.9398

Ratio between broad-narrow spectrum antibiotic use (ratio)

broad /narrow	2.4977*** (1.65, 3.34)	0.0032 (-0.05, 0.06)	1.8747** (0.78, 2.97)	0.0500 (-0.02, 0.12)	1.9345
---------------	---------------------------	-------------------------	--------------------------	----------------------	--------

Use of oral and parenteral antibiotics (expressed in DID)

Oral	5.6076*** (4.73, 6.48)	0.0221 (-0.03, 0.08)	-1.9292** (-3.09, -0.77)	-0.0815* (-0.15, -0.01)	1.9424
Parenteral	5.1721*** (4.63, 5.71)	0.0011 (-0.03, 0.03)	-0.5049 (-1.22, 0.21)	-0.0373 (-0.08, 0.00)	2.2052

555 Notes: *p<0.05; **p<0.01; ***p<0.001;

556 CI: confidence intervals; DW: Durbin-Watson

557

Figures




Figure 1

Monthly antibiotic consumption of J01 Total, J01C, J01M, J01D and J01F




Figure 2

Monthly relative contributions of J01CE, J01CR, J01DD/DE, J01MA of total J01 use




Figure 3

Monthly broad- and narrow-spectrum antibiotic consumption as well as the ratio between them




Figure 4

Monthly antibiotic consumption of oral and parenteral antibiotics